Literature DB >> 3275896

Effect of transplantation on the Medicare end-stage renal disease program.

P W Eggers1.   

Abstract

The Medicare end-stage renal disease program has received considerable attention as a model of government funding for high-cost medical treatment. This paper examines how the program has been influenced by renal transplantation. In the past decade, the number of kidney transplantations has increased substantially, and the success rate of these procedures has improved. From 1980 to 1985, the number of transplantations increased by 10 percent per year. During that time, the survival rates for grafts from cadavers and living related donors increased by 7 and 3 percent, respectively, in part because of the introduction of cyclosporine. As a result, the fastest-growing group of beneficiaries of the Medicare end-stage renal disease program are those with functioning grafts. As of the end of 1985, these patients accounted for 18 percent of all beneficiaries and 32 percent of all beneficiaries less than 55 years of age. In the youngest groups, transplantation has reached a level sufficient to reduce the absolute numbers of patients on dialysis, beginning in 1983. Increases in transplantation are not evenly distributed among subgroups of beneficiaries. Relatively few patients 65 years of age and older receive transplants; blacks receive transplants at a rate roughly half that among whites, but the rate is increasing. Because the costs of maintaining patients with functioning grafts are only one third of those for patients on dialysis and because the quality of life is usually much better, renal transplantation is causing a convergence of the best clinical and economic outcomes for patients with end-stage renal disease.

Entities:  

Mesh:

Year:  1988        PMID: 3275896     DOI: 10.1056/NEJM198801283180406

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  41 in total

1.  Racial disparities in access to renal transplantation--clinically appropriate or due to underuse or overuse?

Authors:  A M Epstein; J Z Ayanian; J H Keogh; S J Noonan; N Armistead; P D Cleary; J S Weissman; J A David-Kasdan; D Carlson; J Fuller; D Marsh; R M Conti
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

2.  What can Europeans learn from Americans?

Authors:  A C Enthoven
Journal:  Health Care Financ Rev       Date:  1989-12

3.  Protocol of the KTFT-TALK study to reduce racial disparities in kidney transplant evaluation and living donor kidney transplantation.

Authors:  Kellee Bornemann; Emilee Croswell; Menna Abaye; Cindy L Bryce; Chung-Chou H Chang; Deborah S Good; Cathleen A Freehling Heiles; Mary Amanda Dew; L Ebony Boulware; Amit D Tevar; Larissa Myaskovsky
Journal:  Contemp Clin Trials       Date:  2016-12-05       Impact factor: 2.226

Review 4.  Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation.

Authors:  J E Frampton; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

5.  High-tech medicine and the control of health care costs.

Authors:  C R Stiller
Journal:  CMAJ       Date:  1989-04-15       Impact factor: 8.262

Review 6.  Costs of insulin-dependent diabetes mellitus.

Authors:  T T Simell; H Sintonen; J Hahl; O G Simell
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

7.  Parental attitudes toward organ transplantation.

Authors:  S H Meisler; H Trachtman
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

Review 8.  Non-medical factors influencing access to renal transplantation.

Authors:  Eszter Panna Vamos; Marta Novak; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-04-07       Impact factor: 2.370

9.  Benefits Improvement and Protection Act's impact on transplantation rates among elderly MEDICARE beneficiaries with end-stage renal disease.

Authors:  C Daniel Mullins; Rahul Jain; Matthew R Weir; Christine S Franey; Ya-Chen Tina Shih; Françoise G Pradel; Kaloyan Bikov; Stephen T Bartlett
Journal:  Transplantation       Date:  2013-02-15       Impact factor: 4.939

10.  Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients.

Authors:  M A Gall; P Rossing; P Skøtt; P Damsbo; A Vaag; K Bech; A Dejgaard; M Lauritzen; E Lauritzen; P Hougaard
Journal:  Diabetologia       Date:  1991-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.